CORRECTIONS

Author Corrections

The November 1999 article by Bubley et al, entitled, “Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group” (J Clin Oncol 17:3461-3467, 1999), contained an error.

The legend of Figure 1 was given as: “If the PSA at time point no. 3 (value no. 3A) is greater than at time point no. 2,

then the requirement for a sequence of three increases has been met.”

Whereas it should have been:

“If the PSA at time point no. 3 (value no. 3A) is greater than at time point no. 2, then the requirement for a sequence of **two** increases has been met.”

The authors apologize for the mistake.

DOI: 10.1200/JCO.2013.50.2989; published May 1, 2013

The January 10, 2013 article by Weitzel et al, entitled, “Prevalence and Type of *BRCA* Mutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genetics Community Research Network” (J Clin Oncol 31:210-216, 2013), contained an error.

In the sidebar of the article, support was acknowledged from the American Cancer Society Grant No. RSGT-00-263-01, whereas it should have been the American Cancer Society Grant No. RSGT-**09**-263-01.

The authors apologize for the mistake.

DOI: 10.1200/JCO.2013.50.2997; published May 1, 2013

Journal Correction

The March 1, 2013 article by Lefebvre et al, entitled, “Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study” (J Clin Oncol 31:853-859, 2013), contained errors.

In Table 5, under local failure and regional failure, the data for surgery feasible and surgery successful were incorrectly displayed. The corrected table is reprinted below in its entirety, with the corrections given in bold.

Journal of Clinical Oncology apologizes for the mistakes.

DOI: 10.1200/JCO.2013.50.2971; published May 1, 2013

Table 5. Treatment Failures and Salvage Surgery

Variable	Patients 18 Months Post-Treatment				Patients at Last Evaluation*			
	Cisplatin		Cetuximab		Cisplatin		Cetuximab	
	No.	%	No.	%	No.	%	No.	%
Local (with or without regional) failure	5†	8.3	8	14.3	8	13.3	12	21.4
Surgery feasible	0		7		1		9‡	
Surgery successful					0		6	
Ultimate local failure					8	13.3	6	10.7
Regional failure only	5	8.3	5	8.9	4	6.7	5	8.9
Surgery feasible					1		4	
Surgery successful					0		1	
Ultimate regional failure					4		4	
Distant metastases					5	8.3	3	5.4
Second primary cancer					7	11.7	8	14.3

*Median follow-up, 36 months; maximum follow-up, 58 months in each arm.

†One patient with uncontrolled disease lost to follow-up.

‡One patient refused all further treatment, including salvage surgery.